Hyperhidrosis
Drug research and approvals for hyperhidrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 3 studies of hyperhidrosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 3
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 3 recruiting on ClinicalTrials.gov ↗- Botulinum Toxin Type A for Frontal HyperhidrosisNCT07561580 · Not applicable · Latakia University · starts Nov 20, 2025
- A Polymer Film Device to Treat Excessive Palmar SweatingNCT06881394 · Not applicable · Miller Biosciences LLC · starts Jul 3, 2024
- Targeting Nociceptors in Hidradenitis SuppurativaNCT05403710 · Not reported · University of Massachusetts, Worcester · starts Jun 7, 2022
Drug Pipeline
2 approved, 2 in phase 3, 4 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Sofpironium, Glycopyrronium
- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Oxybutynin
- Phase 3 Muscarinic acetylcholine receptor M3 antagonist
- Umeclidinium
- Phase 2 Muscarinic acetylcholine receptor M3 antagonist
- Botulinum toxin type a
- Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
- Dexmecamylamine
- Phase 2 Neuronal acetylcholine receptor; alpha4/beta2 antagonist
- Rimabotulinumtoxinb
- Phase 2 Vesicle-associated membrane protein 2 inhibitor
- Alcohol
- Phase 1
- Aluminum chloride anhydrous
- Phase 1
How Its Trials Ended
110 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 20 whose ending is known, 55% met their primary endpoint, 0% missed it and 45% stopped early.
- Completed, result not reported7467%
- Met its primary endpoint1110%
- Ongoing87%
- Status unknown87%
- Stopped: other or unclear44%
- Stopped: sponsor or business decision33%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Oct 20, 2015 | A phase 2a study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied umeclidinium/gsk573719 in subjects with primary…Umeclidinium | GSK | Closed |
| May 1, 2014 | A phase 2, randomized, double-blind, vehicle controlled, comparator study of the effect of drm04b and drm04 in subjects with axillary hyperhidrosisGlycopyrronium (DRM04) /glycopyrrolate | Dermira Incorporated | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA